Most Read Articles
4 days ago

Dr Michael Lim, a senior consultant at the Paediatric Pulmonary and Sleep Division, National University Hospital, Singapore, speaks to Roshini Claire Anthony on the rare disease that is cystic fibrosis.

2 days ago
Susceptibility‐guided therapy is as effective as empiric modified bismuth quadruple therapy for the first-line treatment of Helicobacter pylori infection, with both yielding excellent eradication rates, as shown in a recent trial.
4 days ago
It appears that long-term consumption of fish and omega-3 fatty acid does not influence the risk of incident hypertension in middle-aged and older men, suggests a US study.
2 days ago
The risk factors and outcomes associated with an increased risk of permanent pacing include atrial fibrillation (AF) ablation, multivalve surgery and New York Heart Association (NYHA) functional class III/IV, a recent study has found.

Ranolazine effective for angina in ischaemic patients

13 Jan 2019

Ranolazine improves angina and myocardial perfusion in patients with signs of ischaemia with coronary flow reserve (CFR) <2.5 and without obstructive coronary artery disease (CAD), reports a new study.

A total of 81 patients (mean age 54.77±10.19 years; 98.8 percent female) were enrolled in whom the mean baseline CFR was 2.69±0.65. More than half (56.8 percent; n=46) had CFR values ≥2.5, while the remaining 35 (43.2 percent) had CFR <2.5.

Ranolazine significantly improved angina, measured using the Seattle Angina Questionnaire (SAQ-7), relative to placebo in patients with CFR <2.5 (change, 5.76±11.51 vs –0.86±13.45; p=0.028). A similar effect was observed on SAQ angina frequency (change, 9.14±17.55 vs –0.29±14.24 p=0.0073).

Notably, no such effects were observed for patients with CRF ≥2.5. Ranolazine likewise had no significant effect on physical limitation, angina stability, quality of life and treatment satisfaction.

Researchers also observed a significant effect of ranolazine on global myocardial perfusion reserve index (MPRI), which significantly improved in those with CFR <2.5 (change: 0.12±0.58) but decreased in patients with CFR 2.5 (change: –0.15±0.44; t test p=0.02). The same was true for midventricular MPRI (change: 0.27±0.68 and –0.11±0.5, respectively; t test p=0.005).

There was also a direct association between elevated MPRI values and improvements in symptoms, suggesting a link between angina and ischaemia, said researchers. The present findings also showed the potential of late sodium channel inhibition as a management option in these patients.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
4 days ago

Dr Michael Lim, a senior consultant at the Paediatric Pulmonary and Sleep Division, National University Hospital, Singapore, speaks to Roshini Claire Anthony on the rare disease that is cystic fibrosis.

2 days ago
Susceptibility‐guided therapy is as effective as empiric modified bismuth quadruple therapy for the first-line treatment of Helicobacter pylori infection, with both yielding excellent eradication rates, as shown in a recent trial.
4 days ago
It appears that long-term consumption of fish and omega-3 fatty acid does not influence the risk of incident hypertension in middle-aged and older men, suggests a US study.
2 days ago
The risk factors and outcomes associated with an increased risk of permanent pacing include atrial fibrillation (AF) ablation, multivalve surgery and New York Heart Association (NYHA) functional class III/IV, a recent study has found.